Literature DB >> 23434225

Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors.

Melissa A VanAlstine1, Mark P Wentland, Juan Alvarez, Qing Cao, Dana J Cohen, Brian I Knapp, Jean M Bidlack.   

Abstract

Derivatives of the lead compound N-BPE-8-CAC (1) where each CH of the biphenyl group was individually replaced by N were prepared in hopes of identifying high affinity ligands with improved aqueous solubility. Compared to 1, binding affinities of the five possible pyridinyl derivatives for the μ opioid receptor were between threefold lower to fivefold higher with the Ki of the most potent compound being 0.064 nM. Docking of 8-CAC (2) into the unliganded binding site of the mouse μ opioid receptor (pdb: 4DKL) revealed that 8-CAC and β-FNA (from 4DKL) make nearly identical interactions with the receptor. However, for 1 and the new pyridinyl derivatives 4-8, binding is not tolerated in the 8-CAC binding mode due to the steric constraints of the large N-substituents. Either an alternative binding mode or rearrangement of the protein to accommodate these modifications may account for their high binding affinity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23434225      PMCID: PMC3602279          DOI: 10.1016/j.bmcl.2013.01.117

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.

Authors:  John L Neumeyer; Ao Zhang; Wennan Xiong; Xiao-Hui Gu; James E Hilbert; Brian I Knapp; S Stevens Negus; Nancy K Mello; Jean M Bidlack
Journal:  J Med Chem       Date:  2003-11-20       Impact factor: 7.446

2.  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine.

Authors:  Mark P Wentland; Melissa VanAlstine; Robert Kucejko; Rongliang Lou; Dana J Cohen; Amy L Parkhill; Jean M Bidlack
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

Review 3.  Cyclazocine revisited.

Authors:  S Archer; S D Glick; J M Bidlack
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

4.  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC.

Authors:  Mark P Wentland; Sunjin Jo; Joseph M Gargano; Melissa A VanAlstine; Dana J Cohen; Jean M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2012-10-27       Impact factor: 2.823

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines.

Authors:  M P Wentland; R Lou; Y Ye; D J Cohen; G P Richardson; J M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2001-03-12       Impact factor: 2.823

7.  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC.

Authors:  Melissa A VanAlstine; Mark P Wentland; Dana J Cohen; Jean M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2007-09-29       Impact factor: 2.823

8.  Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Authors:  Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; Jesper M Mathiesen; Roger K Sunahara; Leonardo Pardo; William I Weis; Brian K Kobilka; Sébastien Granier
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.